H-CYTE, Inc. (OTCMKTS:HCYTD – Get Free Report) fell 49.5% on Wednesday . The stock traded as low as $2.02 and last traded at $2.02. 400 shares traded hands during mid-day trading, an increase of 288% from the average session volume of 103 shares. The stock had previously closed at $4.00.
H-CYTE Trading Down 49.5 %
The firm has a fifty day moving average of $2.02 and a 200-day moving average of $2.02.
About H-CYTE
H-CYTE, Inc, a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease.
See Also
- Five stocks we like better than H-CYTE
- What is the S&P 500 and How It is Distinct from Other Indexes
- Hedge Funds Boost Oil Positions: Is a Major Rally on the Horizon?
- Where to Find Earnings Call Transcripts
- Power Play: Japan’s Top Auto Stocks Eye Historic Merger
- Consumer Discretionary Stocks Explained
- S&P 500 Earnings Set to Shine: January’s Critical Market Test
Receive News & Ratings for H-CYTE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H-CYTE and related companies with MarketBeat.com's FREE daily email newsletter.
